Actively Recruiting
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Led by Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Updated on 2022-05-10
352
Participants Needed
1
Research Sites
465 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
CONDITIONS
Official Title
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed non-keratinizing nasopharyngeal carcinoma (WHO II or III)
- Clinical stage III-IVa (except T3-4N0) based on 8th edition AJCC system
- No distant metastasis present (M0)
- Aged between 18 and 65 years
- White blood cell count ≥ 4 × 10^9/L, platelets ≥ 100 × 10^9/L, and hemoglobin ≥ 90 g/L
- Normal liver function (TBIL, ALT, AST ≤ 2.5 times upper limit of normal)
- Normal kidney function (creatinine ≤ 1.5 times upper limit of normal or creatinine clearance ≥ 60 ml/min)
- Performance status with Karnofsky score above 70
- Signed informed consent provided
You will not qualify if you...
- Keratinizing nasopharyngeal carcinoma (WHO I)
- Age under 18 or over 65 years
- Treatment intended for palliation
- Previous cancer except treated basal or squamous skin cancer or in situ cervical cancer
- Previous radiotherapy, chemotherapy, or surgery (except diagnostic) for primary tumor or nodes
- Current pregnancy or breastfeeding
- Severe ongoing illnesses such as unstable heart disease, acute lung conditions requiring hospitalization, active hepatitis, or mental disturbances
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of radiotherapy(Section 5),Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Guangzhou, Guangdong, China, 510095
Actively Recruiting
Research Team
J
Jinquan Liu, M.D
CONTACT
B
Bin Qi, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here